Nijmegen, Groningen, Weert (The Netherlands), Prague (Czech Republic) –March 12, 2020
Following the successful acquisition of the cGMP drug substance production site in Weert earlier this year, MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, is pleased to announce the following changes in its organization to position the company for the next phase of growth and development:
On March 1, Dr. Titia Mulders was appointed Managing Director for the sites of MercachemSyncom in Nijmegen and Prague. Titia is a highly experienced R&D executive with a strong track record in global pharmaceutical development (phase 1-4) and related regulatory submissions and approvals (US, EU, Canada/ROW). In her most recent role, she was Vice President Medical & Regulatory Affairs and member of the site leadership team at Sanquin Plasma Products B.V. in Amsterdam. Titia has a Ph.D. in pharmacology and toxicology from the University of Leiden, The Netherlands.
Dr. Robert Hof, currently Chief Operating Officer at MercachemSyncom’s site in Groningen, will succeed Dr. Ton Vries as Managing Director of MercachemSyncom in Groningen. Simultaneously Ton will take on a new role as Head of Technology and Innovation at MercachemSyncom.
Our new site in Weert will be led by Dr. Remy Litjens, Managing Director. Remy has worked at the Weert site since 2007 and has been Site Manager at this facility since 2017.
Together with the new appointments at MercachemSyncom’s sites, the Supervisory Board appointed a global Executive Board to oversee all integrated drug-discovery and -development services activities of the company. Members of the Executive Board are Dr. Eelco Ebbers (CEO), Guillaume Jetten (CFO), and Dr. Frank Leemhuis (Head of Corporate Development).
Eelco commented, “We are very pleased with the appointment of these highly qualified professionals in the leadership team. With the new organizational structure, we have strengthened our organization and we are ready for the further implementation of our growth strategy.”
Alexander Vos, Chairman of the Supervisory Board, added: “We wish all of these executives every success in their new roles. We believe we have built a world-class team and created an effective organizational structure to steer the company towards further success as the leading company in the drug-discovery and -development field and trusted partner for pharma and biotech worldwide.”
MercachemSyncom is the leading mid-sized European contract research organization offering innovative chemistry, medicinal chemistry, early process research services, and GMP production to accelerate the drug discovery and development process in a flexible and cost-effective way. MercachemSyncom offers integrated drug-discovery services from hit to clinic. Working for many pharmaceutical and biotech companies throughout the world, MercachemSyncom is recognized for its high-quality products and services and its unprecedented problem-solving capabilities.
More information on MercachemSyncom can be found on the company website:
Eelco Ebbers, Chief Executive Officer +31 24 3723300